(Albany, United States) As per DelveInsight’s assessment, globally, the Metastatic Castration-Resistant Prostate Cancer Pipeline constitutes 75+ key companies continuously working towards developing 75+ Metastatic Castration-Resistant Prostate Cancer Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the Metastatic Castration-Resistant Prostate Cancer Pipeline Report, detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Metastatic Castration-Resistant Prostate Cancer NDA approvals (if any), and product development activities comprising the technology, Metastatic Castration Resistant Prostate cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

To explore more information on the latest breakthroughs in the Metastatic Castration-Resistant Prostate Cancer Pipeline treatment landscape of the report, click here @ Metastatic Castration-Resistant Prostate Cancer Pipeline Outlook

 

Key Takeaways from the Metastatic Castration-Resistant Prostate Cancer Pipeline Report

• DelveInsight’s Metastatic Castration-Resistant Prostate Cancer Pipeline analysis depicts a robust space with 75+ active players working to develop 75+ pipeline treatment therapies.
• The leading companies working in the Metastatic Castration-Resistant Prostate Cancer Market include Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc., Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, and others.
• Promising Metastatic Castration-Resistant Prostate Cancer Pipeline Therapies in the various stages of development include olaparib, abiraterone acetate, enzalutamide, ZEN003694, Rucaparib, Prednisone, and others.
• On June 2023, Zenith Epigenetics announced a study of phase 2 clinical trials for ZEN003694 and Enzalutamide. This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abiraterone by PCWG3 criteria. Disease must have progressed on only abiraterone by PCWG3 criteria prior to study entry.
• On August 2023, AstraZeneca announced a study of phase 3 clinical trials for olaparib and abiraterone acetate. The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or new hormonal agents (NHAs) at metastatic castration-resistant prostate cancer (mCRPC) stage.

 

Metastatic Castration-Resistant Prostate Cancer Overview

Prostate cancer (PCa) is one of the most prevalent malignancies in the world and the third most common cause of male cancer-related death in the United States of America (USA). The majority of men with newly diagnosed PCa present with localized disease and undergo radical prostatectomy and/or radiological therapy, followed by androgen deprivation therapy (ADT).

 

For further information, refer to the detailed Metastatic Castration-Resistant Prostate Cancer Unmet Needs, click here for Metastatic Castration-Resistant Prostate Cancer Ongoing Clinical Trial Analysis

 

Metastatic Castration-Resistant Prostate Cancer Emerging Drugs Profile

 

• SRF617: Surface Oncology

SRF617 is a fully human antibody designed to inhibit the enzymatic activity of CD39 in the tumor microenvironment, allowing for a dual mechanism of action to promote anti-tumor immunity via reduction of immunosuppressive adenosine in addition to increasing levels of immunostimulatory ATP. SRF617 has been granted Orphan Drug designation for the treatment of advanced pancreatic cancer by the FDA.

 

• Rucaparib: Clovis Oncology

Rucaparib is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed in multiple tumor types, including ovarian and metastatic castration-resistant prostate cancers, as monotherapy, and in combination with other anti-cancer agents. Exploratory studies in other tumor types are also underway.

 

• HP518: Hinova Pharmaceuticals

HP518, a highly selective and orally bioavailable chimeric degrader targeting androgen receptor (AR) with the potential to overcome the drug resistance of prostate cancer due to some specific AR mutations. In discovery and preclinical studies, HP518 showed high degradation activity against wild type AR and some specific AR mutants that are resistant to enzalutamide, and excellent antitumor activity in xenograft mouse models. HP518 is highly selective for AR.

 

Metastatic Castration-Resistant Prostate Cancer Pipeline Therapeutics Assessment

There are approx. 75+ key companies which are developing the therapies Metastatic Castration Resistant Prostate cancer. The companies which have their Metastatic Castration Resistant Prostate cancer drug candidates in the most advanced stage, i.e phase III include Clovis Oncology

 

Request a sample and discover the recent advances in Metastatic Castration-Resistant Prostate Cancer Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Metastatic Castration-Resistant Prostate Cancer Segmentation

 

Metastatic Castration-Resistant Prostate Cancer Drugs and Companies

• Olaparib: AstraZeneca
• Abiraterone acetate: Merck Sharp & Dohme LLC
• Enzalutamide: Astellas Pharma Europe Ltd.

 

Metastatic Castration-Resistant Prostate Cancer Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Metastatic Castration-Resistant Prostate Cancer Therapeutics Market include-

Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc., Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, and others.

 

Dive deep into rich insights for drugs for Metastatic Castration-Resistant Prostate Cancer Pipeline, click here @ Metastatic Castration-Resistant Prostate Cancer Unmet Needs and Analyst Views

 

Scope of the Metastatic Castration-Resistant Prostate Cancer Pipeline Report

• Coverage- Global
• Companies- Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc., Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, and others.
• Therapies- olaparib, abiraterone acetate, enzalutamide, ZEN003694, Rucaparib, Prednisone, and others.
• Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Metastatic Castration-Resistant Prostate Cancer Merger and acquisitions, Licensing Activities

 

Table of Content

1. Introduction
2. Executive Summary
3. Metastatic Castration Resistant Prostate cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Metastatic Castration Resistant Prostate cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Rucaparib: Clovis Oncology
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Surface Oncology: SRF 617
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. REGN 4336: Regeneron Pharamceuticals
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. HP 518: Hinova Pharmaceuticals
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Metastatic Castration Resistant Prostate cancer Key Companies
21. Metastatic Castration Resistant Prostate cancer Key Products
22. Metastatic Castration Resistant Prostate cancer- Unmet Needs
23. Metastatic Castration Resistant Prostate cancer- Market Drivers and Barriers
24. Metastatic Castration Resistant Prostate cancer- Future Perspectives and Conclusion
25. Metastatic Castration Resistant Prostate cancer Analyst Views
26. Metastatic Castration Resistant Prostate cancer Key Companies
27. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services